Cargando…

Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes

OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: Dørflinger, Gry Høst, Holt, Charlotte Brink, Thiel, Steffen, Østergaard, Jakob Appel, Hansen, Troels Krarup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727755/
https://www.ncbi.nlm.nih.gov/pubmed/29318157
http://dx.doi.org/10.1155/2017/1249729
_version_ 1783285949639163904
author Dørflinger, Gry Høst
Holt, Charlotte Brink
Thiel, Steffen
Østergaard, Jakob Appel
Hansen, Troels Krarup
author_facet Dørflinger, Gry Høst
Holt, Charlotte Brink
Thiel, Steffen
Østergaard, Jakob Appel
Hansen, Troels Krarup
author_sort Dørflinger, Gry Høst
collection PubMed
description OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. METHODS: We measured MBL, fructosamine, and HbA(1c)at baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. RESULTS: After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P < 0.0001). There was a significant decrease in HbA(1c) from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P < 0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P < 0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P = 0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA(1c), or fructosamine. CONCLUSIONS: MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control.
format Online
Article
Text
id pubmed-5727755
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57277552018-01-09 Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes Dørflinger, Gry Høst Holt, Charlotte Brink Thiel, Steffen Østergaard, Jakob Appel Hansen, Troels Krarup J Diabetes Res Clinical Study OBJECTIVE: Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. METHODS: We measured MBL, fructosamine, and HbA(1c)at baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. RESULTS: After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P < 0.0001). There was a significant decrease in HbA(1c) from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P < 0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P < 0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P = 0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA(1c), or fructosamine. CONCLUSIONS: MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control. Hindawi 2017 2017-11-26 /pmc/articles/PMC5727755/ /pubmed/29318157 http://dx.doi.org/10.1155/2017/1249729 Text en Copyright © 2017 Gry Høst Dørflinger et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Dørflinger, Gry Høst
Holt, Charlotte Brink
Thiel, Steffen
Østergaard, Jakob Appel
Hansen, Troels Krarup
Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title_full Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title_fullStr Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title_full_unstemmed Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title_short Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
title_sort effect of optimization of glycaemic control on mannan-binding lectin in type 1 diabetes
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727755/
https://www.ncbi.nlm.nih.gov/pubmed/29318157
http://dx.doi.org/10.1155/2017/1249729
work_keys_str_mv AT dørflingergryhøst effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes
AT holtcharlottebrink effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes
AT thielsteffen effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes
AT østergaardjakobappel effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes
AT hansentroelskrarup effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes